×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ALEC

Alector Stock Forecast, Price & News

$11.02
+0.86 (+8.46%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.09
$11.08
50-Day Range
$7.65
$11.02
52-Week Range
$7.50
$43.32
Volume
641,758 shs
Average Volume
720,456 shs
Market Capitalization
$918.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.86

Alector Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
170.9% Upside
$29.86 Price Target
Short Interest
Bearish
9.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1.54 K Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.21 out of 5 stars

Medical Sector

355th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

56th out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Alector logo

About Alector (NASDAQ:ALEC)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock News Headlines

Alector (NASDAQ:ALEC) Shares Up 7.9%
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
208
Year Founded
N/A

Company Calendar

Last Earnings
11/04/2021
Today
7/02/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$29.86
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+170.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
6 Analysts

Profitability

Net Income
$-36.33 million
Pretax Margin
-12.32%

Debt

Sales & Book Value

Annual Sales
$207.09 million
Book Value
$3.70 per share

Miscellaneous

Free Float
71,661,000
Market Cap
$918.26 million
Optionable
Not Optionable
Beta
1.37














Alector Frequently Asked Questions

Should I buy or sell Alector stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Alector stock.
View analyst ratings for Alector
or view top-rated stocks.

What is Alector's stock price forecast for 2022?

6 brokers have issued 1-year price objectives for Alector's stock. Their ALEC stock forecasts range from $6.00 to $57.00. On average, they predict Alector's stock price to reach $29.86 in the next twelve months. This suggests a possible upside of 170.9% from the stock's current price.
View analysts' price targets for Alector
or view top-rated stocks among Wall Street analysts.

How has Alector's stock performed in 2022?

Alector's stock was trading at $20.65 at the beginning of 2022. Since then, ALEC stock has decreased by 46.6% and is now trading at $11.02.
View the best growth stocks for 2022 here
.

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alector
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $1.95. The company earned $182.41 million during the quarter, compared to analyst estimates of $407.41 million. Alector had a negative net margin of 12.65% and a negative trailing twelve-month return on equity of 10.57%.
View Alector's earnings history
.

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman Ulf Gerngross Ph.D., Co-Founder & Chairman (Age 58, Pay $60k)
  • Dr. Arnon Rosenthal Ph.D., Co-Founder, CEO & Director (Age 66, Pay $972.75k)
  • Dr. Sara Kenkare-Mitra Ph.D., Pres and Head of R&D (Age 54, Pay $552.78k)
  • Mr. Calvin Yu, VP of Fin. (Age 46, Pay $519.69k) (LinkedIn Profile)
  • Dr. Robert S. King, Chief Devel. Officer (Age 59, Pay $658.84k) (LinkedIn Profile)
  • Dr. Marc Grasso M.D., Chief Financial Officer (Age 48)
  • Michelle Corral, VP of Communications & Investor Relations
  • Ms. Danielle Pasqualone J.D., Ph.D., Interim Gen. Counsel
  • Erica Jefferson, VP of Communications & Public Affairs
  • Ms. Clare Hunt M.B.A., Head of People

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $11.02.

How much money does Alector make?

Alector (NASDAQ:ALEC) has a market capitalization of $918.26 million and generates $207.09 million in revenue each year. The company earns $-36.33 million in net income (profit) each year or ($0.420010) on an earnings per share basis.

How many employees does Alector have?

Alector employs 208 workers across the globe.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.

This page (NASDAQ:ALEC) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.